Health Canada has announced that a court has approved the agency's request for a permanent ban on Canlab Research, a Quebec-based online store, from selling unauthorized injectable peptides in the country. The decision comes as part of ongoing efforts by Health Canada to address the growing wellness trend associated with these substances.
The federal agency indicated that the Superior Court of Québec granted a permanent injunction against Canlab in June, which prohibits the company from manufacturing, testing, distributing, or selling unauthorized injectable peptides. Furthermore, Canlab is also barred from assisting others in similar activities. The injunction extends to all forms of advertising on social media platforms and websites accessible to Canadian residents.
For several years, Health Canada has been warning consumers against purchasing unauthorized injectable peptides from Canlab Research, citing the promotion of unverified health claims on various online platforms. A temporary injunction had already been issued against the company in 2024 as part of Health Canada's strategy to curb such practices.
The permanent injunction emphasizes that Canlab must adhere to the court's directives. The company’s website currently redirects visitors to a legal notice dated April 2025, which confirms compliance with the court's orders and expresses Canlab's commitment to transparency, regulatory compliance, and maintaining trust among its global customer base.
Injectable peptides, which are short chains of amino acids, serve essential functions in the human body and have gained popularity in recent years. They are often marketed as solutions for various health issues, including anti-aging, weight loss, injury recovery, and improved sleep. However, Health Canada has stressed the potential dangers associated with unauthorized injectable peptides.
In April, the agency released a public advisory highlighting the risks posed by these unauthorized products. Health Canada warned that they could lead to severe health complications, including hormonal imbalances, mood swings, blood sugar dysregulation, liver or kidney damage, blood clots, and even the growth of cancerous tumors. As a precautionary measure, the agency encourages Canadians to purchase prescription medications solely from licensed pharmacies and to verify a drug's legality by checking for its eight-digit drug identification number.
In summary, Health Canada's decisive action against Canlab Research reflects its commitment to safeguarding public health by ensuring that only authorized and properly regulated medications are available to Canadian consumers. The agency’s focus on preventing the sale of unproven health products underscores the importance of regulatory oversight in the wellness industry, especially in light of the potential risks associated with unauthorized injectable peptides.
